Last reviewed · How we verify
NCT04872114: SMART-HD
Sympathetic Mapping/ Ablation of Renal Nerves Trial - Hemodialysis
NA trial testing SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator in Hypertension in 30 participants. Status unknown.
1 May 2023
Quick facts
| Lead sponsor | The Second Hospital of Nanjing Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 May 2021 |
| Primary completion | 1 May 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Conditions studied
- Hypertension — all drugs for Hypertension →
- Hemodialysis — all drugs for Hemodialysis →
Sponsor
The Second Hospital of Nanjing Medical University
Who can join
Adults 18 to 70, any sex, with Hypertension or Hemodialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I™ in patients on hemodialysis with pharmacotherapy and uncontrolled hypertension for at least 6 months, then after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days, office systolic blood pressure (BP) is still ≥ 150mmHg, ≤180mmHg.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04872114
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Trials testing the same drug.
- NCT02761811 — Sympathetic Mapping/ Ablation of Renal Nerves Trial · NA · active not recruiting
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other The Second Hospital of Nanjing Medical University trials
Trials by the same sponsor.
- NCT07331688 — CMTS0515-auWMT for Radiation Enteritis · Phase 1, PHASE2 · active not recruiting
- NCT06839586 — CMTS4520 for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · active not recruiting
- NCT06839599 — CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults · Phase 1, PHASE2 · not yet recruiting
- NCT06844708 — CMTS0929 for Inflammatory Bowel Disease · EARLY_PHASE1 · not yet recruiting
- NCT06836427 — CMTS0929 for Clostridioides Difficile Infection · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04872114 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Nanjing Medical University
- Last refreshed: 4 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04872114.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing